Previous close | 1.0700 |
Open | 1.0600 |
Bid | 0.9485 x 200 |
Ask | 0.9855 x 200 |
Day's range | 0.9327 - 1.0976 |
52-week range | 0.3330 - 19.4700 |
Volume | |
Avg. volume | 2,814,580 |
Market cap | 97.22M |
Beta (5Y monthly) | 0.74 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.9200 |
Earnings date | 06 May 2024 - 10 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1.75 |
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer have been selected for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois. Details for the poster presentation are as foll
Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.
Ultragenyx (RARE) reports positive interim data from the phase I/II study of GTX-102 for Angelman syndrome. However, the stock declines due to safety concerns.